Items where authors include "Shumel, B."

Article

Cork, M.J. orcid.org/0000-0003-4428-2428, Lockshin, B., Pinter, A. et al. (3 more authors) (2024) Clinically meaningful responses to dupilumab among children aged 6 months to 5 years with moderate-to-severe atopic dermatitis who did not achieve clear or almost clear skin according to the investigator’s global assessment: a post hoc analysis of a phase 3 trial. Acta Dermato-Venereologica, 104. 13467. ISSN 0001-5555

Simpson, E.L., Paller, A.S., Siegfried, E.C. et al. (10 more authors) (2021) Dupilumab demonstrates rapid and consistent improvement in extent and signs of atopic dermatitis across all anatomical regions in pediatric patients 6 years of age and older. Dermatology and Therapy, 11. pp. 1643-1656. ISSN 2193-8210

Silverberg, J.I., Simpson, E.L., Guttman-Yassky, E. et al. (15 more authors) (2021) Dupilumab significantly modulates pain and discomfort in patients with atopic dermatitis : a post hoc analysis of 5 randomized clinical trials. Dermatitis, 32 (1S). S81-S91. ISSN 1710-3568

Paller, A.S., Wollenberg, A., Siegfried, E. et al. (12 more authors) (2021) Laboratory safety of dupilumab in patients aged 6–11 years with severe atopic dermatitis : results from a phase III clinical trial. Pediatric Drugs, 23 (5). pp. 515-527. ISSN 1174-5878

Paller, A.S., Siegfried, E.C., Thaçi, D. et al. (22 more authors) (2020) Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. Journal of the American Academy of Dermatology, 83 (5). pp. 1282-1293. ISSN 0190-9622

Akinlade, B., Guttman-Yassky, E., de Bruin-Weller, M. et al. (25 more authors) (2019) Conjunctivitis in dupilumab clinical trials. British Journal of Dermatology, 181 (3). pp. 459-473. ISSN 0007-0963

de Bruin-Weller, M., Thaçi, D., Smith, C.H. et al. (12 more authors) (2018) Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo‐controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). British Journal of Dermatology , 178 (5). pp. 1083-1101. ISSN 0007-0963